• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Cannabis

Aurora Cannabis' Cash Burn Is Harsh

The cannabis company is now putting its focus on premium products since the value side fell apart.
By DEBRA BORCHARDT
Nov 11, 2020 | 02:30 PM EST
Stocks quotes in this article: ACB

Aurora Cannabis (ACB) is burning more money than its customers are burning cannabis.

The company announced a $125 million offering sending the shares down by over 20%. This is coming on the heels of the company saying that revenue was going to be falling.

The news prompted Stifel analyst Andrew Carter to put a "Sell" rating on the stock. He wrote, "We were perplexed when the company announced that it had exhausted its ATM facility in late October. The implied cash burn through the first 37 days of the quarter (C$83 million with just over C$20 million in unique items) suggests cash needs outside the scope of our expectations with the ATM exhaustion following fourth quarter earnings at roughly C$6.40 per share now seemingly pragmatic."

The analyst suggested that the offering implied a sense of urgency. He has a target price now of C$6.50. His breakdown is as follows: C$308 million of cash, C$31 million for inventory, C$444 million for property and equipment, C$150 million for intellectual property, C$240 million for the Canadian medical platform and C$70 million for the German distribution business. "We net this total C$1.2 billion in liquidation value against nearly C$600 million in liabilities," he wrote. His sum-of-the parts analysis implies a value of C$4 per share.

Carter now estimates sales for fiscal year 2021 will be C$309 million, down from C$326 million. Fiscal year 2022 sales are now estimated to be C$435 million down from the previous estimate of C$462 million. He did give that a caveat that is assuming Aurora keeps pace with its competition as competing in Canada is becoming an expensive endeavor. Keep in mind that the Canadian market is growing, but Aurora's revenue, albeit a large number, is falling.

Cantor Fitzgerald Stays Neutral

Cantor Fitzgerald is keeping its "Neutral" rating on Aurora and analyst Pablo Zuanic wrote, "Despite the swings in the stock in recent days, we are only tweaking our 12-month PT to C$12 from C$13 (due to the higher share count), taking 20x on our forward EBITDA estimates (Dec 2021 to Nov 2022). Ex-guidance/expectations, in our view, the Sep qtr print brought disappointment in several ways: a sales drop in domestic rec/med, with clear rec share loss, margins worsened and so did cash burn."

His arithmetic for the valuation was as follows: "Taking the US$125Mn equity offering price of US$7.50 (10% discount to Tuesday's close), 177mn shares, and the new proforma net debt of $41Mn, ACB trades at 6.7x EV/current sales compared with 7x for TLRY and 8x for APHA and VFF (CPG-based stocks like CRON and WEED trade at 40x and 19x). The volatility notwithstanding, we think the relative valuation leaves little downside."

Misunderstanding the Market

In September, Aurora noted that its medical cannabis business has remained steady, but that its retail business continued to have problems. The company focused its efforts on the value brand Daily Special. CFO Glen Ibbott said, "Daily Special our value brand accounted for 62% of total net consumer revenue from flower in the quarter as compared to 35% in the third quarter. This is the primary factor impacting the decline in our average selling price per gram of dried cannabis flower."

The company also noted that once it began to focus on a value brand that its competitors did as well. Ibbott added, "I think the company got a bit distracted by the success that they saw with that discount offering which was Daily Special, which sort of delayed other endpoints such as vapor and pre-rolls. There is a lot of growth in the category and then everyone else kept piling in and because there with such a reliance upon that discount business and a lot of different ways both on the gross side, on the sales side, on the trade marketing side when that was just completely you know pressed against by competitive pricing pressure it became hard to pivot."

Aurora is now putting its focus on premium products since the value side fell apart. However, it isn't that simple to move the focus from cheap cannabis to a product that repeat customers are willing to spend lots of money on. Aurora CEO Miguel Martin said on the company's earnings call, "What I can tell you is that you are going to see a significant focus on our premium flower and then we have some tremendous brands, as you know, Whistler, San Raf and Aurora. First and foremost, it takes a little bit to get those premium brands we settled. Secondly, we have had very substantive and good conversations with our trade partners about that. And third, we have to look at in some ways, looking into better articulation on format and packaging, and those things take a little bit longer than just flipping a switch and saying we care about San Raf, Whistler and Aurora."

While the premium market is lucrative, it is a smaller group of consumers. A regular cannabis consumer that is going to a dispensary two to three times a month begins to make a value price decision when choosing a product. Often the choice is for the lower priced product.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Debra Borchardt has no position in the company mentioned in this story.

TAGS: Earnings | Investing | Markets | Analyst Actions | Cannabis

More from Cannabis

I'm Coming Back Around to LiDAR Related Names

Timothy Collins
Jan 13, 2021 1:01 PM EST

Three stocks top my list for plays: Velodyne Lidar, Luminar Technologies, and Collective Growth Crop.

Jushi Holdings Puts Growth Plans in High Gear

Debra Borchardt
Jan 13, 2021 10:00 AM EST

The cannabis cultivator and retailer plans to nearly double its number of dispensaries in 2021.

As the Focus on Psychedelic Stocks Increases, So Do the Valuations

Debra Borchardt
Jan 11, 2021 4:30 PM EST

The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.

Democrat Wins Means Cannabis Wins

Debra Borchardt
Jan 9, 2021 8:15 AM EST

Georgia's election results have given the industry a big green light, meaning positive moves are expected out of cannabis stocks.

Constellation Brands Makes a Major Upside Breakout

Bruce Kamich
Jan 8, 2021 9:04 AM EST

Let's take a fresh look at the charts and indicators.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    When it's time to sell, will you act or freeze?
  • 08:35 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/13/2021

    Lower highs... SPX (Long-Term View) The 1/8/2...
  • 08:07 AM EST GARY BERMAN

    Tuesday Morning Fibocall for 1/12/2021

    Watch if the recent trend of lower highs continues...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login